Tonix Pharmaceuticals Elevates Siobhan Fogarty to CTO Role
Tonix Pharmaceuticals Announces Siobhan Fogarty as CTO
Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development.
Tonix aims for a potential launch of TNX-102 SL, targeting the management of fibromyalgia, with the U.S. FDA PDUFA goal date set for a future decision.
CHATHAM, N.J. – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company, has announced the promotion of Siobhan Fogarty to Chief Technical Officer (CTO), effective immediately. Having joined Tonix in 2016, Ms. Fogarty previously held the position of Executive Vice President of Product Development. She boasts over 25 years of extensive experience in both pharmaceutical and biotech sectors, contributing to product development, manufacturing, and ensuring quality across various platforms.
In a recent development, the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date for TNX-102 SL, designated for a future decision regarding its marketing authorization. TNX-102 SL is implicated in the treatment regimen for fibromyalgia, a prevalent chronic pain condition that significantly affects women.
Dr. Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, expressed confidence in Ms. Fogarty’s leadership: “Siobhan is an invaluable part of our team, with immense contributions to our growth and success since joining us. We are thrilled that she will be stepping into this pivotal role as our first CTO.” He highlighted Ms. Fogarty's critical influence in shepherding various product developments, particularly with respect to the upcoming marketing authorization for TNX-102 SL.
Siobhan Fogarty's Career Journey
Ms. Fogarty's impressive career commenced at Elan Corporation as a formulation scientist. This role allowed her to cultivate expertise in diverse drug delivery systems, including solids, liquids, IV, and transdermal formulations. At Elan, she was pivotal in moving products from initial concepts to commercial manufacture, both in Ireland and the U.S. Following her time there, she transitioned to Glaxo SmithKline in London, where she served as a manufacturing strategist after the merger with SmithKline Beecham.
Her dedication to product development was evident when she led the establishment of European product development sites for companies such as Fuisz Technologies and Biovail Corporation. These positions entrusted her with directing multidisciplinary teams through the various phases of product development, from early conceptual stages to final registration for commercialization in North America.
Future Directions for Tonix Pharmaceuticals
Throughout her tenure, Siobhan Fogarty also established a consultancy firm, eMSc, offering expert advice to biotech and pharmaceutical companies on product development and quality assurance methodologies. Ms. Fogarty holds a master’s degree in Pharmaceutical Sciences from Trinity College, Dublin, and a primary degree in Industrial Chemistry from the University of Limerick, where she also interned at Pfizer.
Expressing her enthusiasm for the new role, Ms. Fogarty stated, “I am grateful for the incredible eight years I have enjoyed working at Tonix and look forward to the challenges and opportunities of my new role. It’s an honor to be part of such an extraordinary team as we navigate this exciting chapter.”
Tonix's Strategic Goals and Development
Tonix Pharmaceuticals is dedicated to impacting public health through innovative therapies for pain management and vaccines targeting key health challenges. The company's development portfolio is primarily focused on addressing central nervous system (CNS) disorders. Tonix is advancing TNX-102 SL, proposing a treatment pathway for fibromyalgia, bolstered by statistically significant Phase 3 study outcomes, lending weight to the NDA submission aimed at secure FDA approval.
In concert with this, TNX-102 SL has received Fast Track designation for the indication of fibromyalgia. But beyond this, the treatment also seeks to address acute stress reactions and disorders through an initiative supported by the U.S. Department of Defense at the University of North Carolina.
Additional Research and Developments
Tonix's impressive pipeline includes numerous product candidates addressing serious health challenges. For instance, TNX-1300 (cocaine esterase) is currently in Phase 2 development with a specific aim at treating cocaine intoxication. This initiative has garnered FDA Breakthrough Therapy designation, further demonstrating Tonix's commitment to pushing boundaries in medical research.
Furthermore, the company's immunology portfolio, which consists of biologics focusing on preventing organ transplant rejection, autoimmunity, and cancer, highlights their comprehensive approach. A notable example is TNX-1500, designed for therapeutic interventions in autoimmune diseases and allograft rejection prevention.
Tonix also aims to tackle infectious diseases with their vaccine candidate for mpox, TNX-801. Recently, they received a contract from the U.S. DoD’s Defense Threat Reduction Agency (DTRA), aiming to develop broad-spectrum antiviral agents targeting CD45 to enhance military personnel’s readiness against biological threats.
Frequently Asked Questions
What is the recent promotion at Tonix Pharmaceuticals?
Siobhan Fogarty has been promoted to Chief Technical Officer at Tonix Pharmaceuticals.
What is TNX-102 SL?
TNX-102 SL is a treatment candidate for fibromyalgia, currently in development with a future FDA market authorization decision expected.
What are Tonix's primary areas of focus?
Tonix Pharmaceuticals focuses on pain management therapies and solutions for public health challenges, particularly within the CNS disorders spectrum.
What is the significance of the FDA's PDUFA goal date?
The PDUFA goal date is crucial as it indicates when the FDA will decide on the marketing authorization for a drug.
How long has Siobhan Fogarty been with Tonix?
Siobhan Fogarty joined Tonix Pharmaceuticals in 2016, contributing for several years prior to her recent promotion.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
